We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
PDYN | Palladyne AI Corporation | 4.59 | 2.59 | 129.50% | 82,998,474 |
QMCO | Quantum Corporation | 9.11 | 5.09 | 126.62% | 39,407,792 |
NA | Nano Labs Ltd | 8.26 | 3.89 | 89.02% | 2,027,977 |
XCUR | Exicure Inc | 18.60 | 7.74 | 71.27% | 4,356,968 |
SKK | SKK Holdings Limited | 1.75 | 0.65 | 59.09% | 95,057,932 |
WCT | Wellchange Holdings Company Limited | 1.95 | 0.70 | 56.00% | 37,099,414 |
OMER | Omeros Corporation | 10.91 | 3.18 | 41.14% | 3,987,829 |
AMPG | Amplitech Group Inc | 1.19 | 0.341 | 40.16% | 1,278,066 |
REPL | Replimune Group Inc | 14.89 | 3.84 | 34.75% | 5,991,041 |
QSI | Quantum Si Inc | 1.6001 | 0.3901 | 32.24% | 27,104,790 |
VUZI | Vuzix Corporation | 1.71 | 0.41 | 31.54% | 5,185,355 |
HANGZHOU, China, Nov. 22, 2024 /PRNewswire/ -- Nano Labs Ltd (Nasdaq: NA) ("we," the "Company" or "Nano Labs"), a leading fabless integrated circuit design company and product solution provider in China, today announced that it has launched its second-generation V Series products. Powered by the advanced Cuckoo 3.0 chips, such new generation series consisting of V2, V2H and V2X models sets new benchmarks for performance and energy efficiency in the crypto mining industry.
Omeros Corporation (Nasdaq: OMER) today announced an update on its progress toward planned resubmission of its biologics license application (“BLA”) for narsoplimab, the company’s first-in-class antibody targeting MASP-2, the effector enzyme of the lectin pathway of complement, in hematopoietic stem cell transplant-associated thrombotic microangiopathy (“TA-TMA”). In last week’s quarterly earnings release and associated call, Omeros stated that it was awaiting feedback from the U.S. Food and Drug Administration (“FDA”) on the company’s revised statistical analysis plan (“SAP”) for the BLA. Omeros has now received FDA’s response on the revised SAP, has no other presubmission information requests pending and is not ...
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the highlights of an Investor & Analyst event that was hosted in New York City on November 20th, 2024.
CRANFORD, N.J., Nov. 22, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) announced today that it will be executing a reverse stock split of its common stock, par value $0.001 per share, at a ratio of 1-for-25 ("Reverse Stock Split"). Pursuant to the laws of the State of Nevada and subject to prior approval by the Company's Board of Directors, Citius Pharma was not required to obtain shareholder approval to effectuate the Reverse Stock Split. The Reverse Stock Split will become effective at 5:00 pm Eastern Time on November 25, 2024. The Company's common stock ...
Rank | Ticker | Board Name | Posts (24h) |
---|---|---|---|
FNMA | Fannie Mae-No Politics | 75 | |
RDAR | Raadr Inc | 32 | |
COOP | Mr Cooper Group Inc | 31 | |
4 | BIEL | Bioelectronics Corp | 17 |
5 | CGAC | Code Green Apparel Corp | 18 |
6 | RDGL | Vivos Inc | 16 |
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 97,573.63 | -211.31 | -0.22% | 1.92T | 5,387,676,873 |
ETH | Ethereum | 3,356.06 | -41.55 | -1.22% | 402.78B | 2,995,793,886 |
USDT | Tether USD | 1.00 | 0.00 | 0.00% | 119.66B | 532,233,974 |
SOL | Solana | 252.19 | -2.88 | -1.13% | 117.55B | 1,622,275,171 |
BNB | Binance Coin | 659.91 | 8.46 | 1.30% | 103.84B | 743,584,269 |
XRP | Ripple | 1.45 | -0.020 | -1.36% | 80.89B | 2,511,538,941 |
DOGE | Dogecoin | 0.4282 | -0.00228 | -0.53% | 62.19B | 4,063,822,582 |
ADA | Cardano | 1.03 | -0.040 | -3.74% | 36.41B | 1,044,139,411 |
USDC | USD Coin | 1.00 | 0.0001 | 0.01% | 35.55B | 1,055,255,219 |
STETH | stETH | 3,356.55 | -40.07 | -1.18% | 32.84B | 3,055,429 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions